Published • loading... • Updated
ASCO 2026 | Updated Data From an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
The mesutoclax and azacitidine regimen showed high response rates and no dose-limiting toxicities in patients with myelodysplastic syndrome and acute myeloid leukemia.
Summary by WBOC 16
8 Articles
8 Articles
Hastings TribuneReposted by 
The Caledonian Record
The Caledonian RecordASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor ...
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that updated data from the Company's novel BCL2 inhibitor mesutoclax in myelodysplastic…
·Nebraska, United States
Read Full Article
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS a
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that updated data
·New York, United States
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left0Leaning Right1Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
R 20%
Factuality
To view factuality data please Upgrade to Premium
